Beam Therapeutics Inc.

NASDAQ:BEAM

Biotechnology

Healthcare
$21.01 +1.46%

+$0.48 today

Market cap
$2.17B
Beta
2.20
P/E (TTM)
-52.3
EPS (TTM)
-$0.63
52W Low $15.60High $36.44

Volume 4.86M

Average 2.11M

BEAM Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Beam Therapeutics Inc.NASDAQ: BEAM

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense remains negative

Q2 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMJun 2026
$0— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Income Tax Expense vs competitors

How BEAM compares with its peers on the latest reported figures

  • BEAM's LTM Jun 2026 income tax expense of $0 is the 2nd highest of the 9 companies compared; the peer median is $0.
  • Income tax expense amounts to 0.0% of revenue for BEAM, versus a peer median of 0.0%.
BEAM Competitors Peer median
Income Tax Expense for BEAM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRSPCRISPR Therapeutics AGLTM Sep 2026$2.34M -37.1%—9.3%
BEAMBeam Therapeutics Inc.LTM Jun 2026$0 ——0.0%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
EDITEditas Medicine, Inc.LTM Mar 2026$0 ——0.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 -100.0%——
DTILPrecision BioSciences, Inc.LTM Mar 2026$0 ——0.0%
FATEFate Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$550K -6011.1%—4.9%
CLLSCellectis S.A.LTM Mar 2026-$2.16M -919.5%—3.2%
Peer median (excluding BEAM) $0-509.7%—0.0%

Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue51.84M60.92M377.71M63.52M139.74M
Cost of Revenue232.13M311.59M0367.56M22.29M
Gross Profit(180.29M)(250.67M)377.71M(304.04M)117.45M
Gross Margin-347.8%-411.5%100.0%-478.7%84.0%
Research & Development387.09M311.59M437.38M367.56M409.62M
Selling, General & Admin57.22M87.81M116.81M111.53M113.82M
Operating Expenses212.18M87.81M554.19M111.53M501.14M
Depreciation & Amortization7.45M14.15M20.01M21.93M22.29M
EBITDA(230.06M)(271.53M)(111.15M)(354.78M)(13.97M)
EBITDA Margin-443.8%-445.7%-29.4%-558.5%-10.0%
Operating Income(392.47M)(338.48M)(176.49M)(415.57M)(383.69M)
Operating Margin-757.0%-555.6%-46.7%-654.3%-274.6%
Interest Income015.3M46.68M49.09M0
Interest Expense000043.73M
Other Income / Expenses21.83M52.8M45.32M38.87M303.7M
Income Before Tax(370.64M)(285.68M)(131.16M)(376.7M)(79.99M)
Pre-Tax Margin-714.9%-468.9%-34.7%-593.1%-57.2%
Income Tax Expense03.41M1.37M39K0
Net Income(370.64M)(289.09M)(132.53M)(376.74M)(79.99M)
Net Margin-714.9%-474.5%-35.1%-593.1%-57.2%
EPS (Basic)(5.77)(4.13)(1.72)(4.58)(0.81)
EPS (Diluted)(5.77)(4.13)(1.72)(4.58)(0.81)
Weighted Avg Shares64.23M70.02M77.15M82.31M98.91M
Weighted Avg Shares (Diluted)64.23M70.02M77.15M82.31M98.91M

Beam Therapeutics Inc.

NASDAQ:BEAM

Intrinsic Alpha fair value

Locked

Current Price

$21.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.